Archive for the 'Bristol-Myers Squibb' Category

Bristol-Myers Squibb news feed.

Opdivo, Yervoy, and Keytruda: Immunotherapy Options for Mesothelioma

Immunotherapy treatments are becoming known alternatives to chemotherapy in cancer patients who have had little success with traditional cancer treatments. With mesothelioma, often times first line treatments have little effect because the cancer is typically in the advanced stages by the time it is detected.  While there currently is no cure for mesothelioma, scientists and

more

ERBITUX–Cetuximab–Receives FDA Approval to Treat Irinotecan Refractory or Intolerant Metastatic Colorectal Cancer; First-of-its-Kind Antibody Approved for Use in Combination with Irinotecan and As a Single Agent

Related News 2 drugs open a new front in cancer war: Avastin, Erbitux herald revolution that targets cells (free membership required) – March 2, 2004 (Judy Peres, Chicago Tribune). QUOTE:“‘We’re in a new era of drug development for cancer,’ said Dr. Hedy Kindler, director of gastrointestinal oncology at the University of Chicago who has tested

more

Last update: April 01, 2019. 03:30:08 pm.